To get a sense of who is truly in control of Regencell Bioscience Holdings Limited (NASDAQ:RGC), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are individual insiders with 81% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
As a result, insiders scored the highest last week as the company hit US$397m market cap following a 15% gain in the stock.
Let's delve deeper into each type of owner of Regencell Bioscience Holdings, beginning with the chart below.
Check out our latest analysis for Regencell Bioscience Holdings
NasdaqCM:RGC Ownership Breakdown November 16th 2022
What Does The Lack Of Institutional Ownership Tell Us About Regencell Bioscience Holdings?
Institutional investors often avoid companies that are too small, too illiquid or too risky for their tastes. But it's unusual to see larger companies without any institutional investors.
There are many reasons why a company might not have any institutions on the share registry. It may be hard for institutions to buy large amounts of shares, if liquidity (the amount of shares traded each day) is low. If the company has not needed to raise capital, institutions might lack the opportunity to build a position. Alternatively, there might be something about the company that has kept institutional investors away. Institutional investors may not find the historic growth of the business impressive, or there might be other factors at play. You can see the past revenue performance of Regencell Bioscience Holdings, for yourself, below.
NasdaqCM:RGC Earnings and Revenue Growth November 16th 2022
Regencell Bioscience Holdings is not owned by hedge funds. The company's CEO Yat-Gai Au is the largest shareholder with 81% of shares outstanding. With such a huge stake, we infer that they have significant control of the future of the company. It's usually considered a good sign when insiders own a significant number of shares in the company, and in this case, we're glad to see a company insider with such skin in the game. Meanwhile, the second and third largest shareholders, hold 7.6% and 0.05%, of the shares outstanding, respectively.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar.
Insider Ownership Of Regencell Bioscience Holdings
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
It seems that insiders own more than half the Regencell Bioscience Holdings Limited stock. This gives them a lot of power. So they have a US$322m stake in this US$397m business. Most would argue this is a positive, showing strong alignment with shareholders. You can click here to see if those insiders have been buying or selling.
General Public Ownership
The general public-- including retail investors -- own 11% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
Private Equity Ownership
Private equity firms hold a 7.6% stake in Regencell Bioscience Holdings. This suggests they can be influential in key policy decisions. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Like risks, for instance. Every company has them, and we've spotted 2 warning signs for Regencell Bioscience Holdings (of which 1 is a bit unpleasant!) you should know about.
Of course this may not be the best stock to buy. Therefore, you may wish to see our free collection of interesting prospects boasting favorable financials.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
要弄清楚誰真正控制了腦再生科技控股有限公司(納斯達克代碼:RGC),瞭解該公司的所有權結構是很重要的。而持有這塊蛋糕最大份額的是個人內部人士,擁有81%的股份。換句話説,該集團將從他們對公司的投資中獲得最大(或損失最大)。
因此,內部人士上週的得分最高,該公司在股價上漲15%後,市值達到3.97億美元。
讓我們從下面的圖表開始,更深入地研究腦再生科技控股的每一種類型的所有者。
查看我們對腦再生科技控股的最新分析
NasdaqCM:RGC所有權明細2022年11月16日
機構所有的缺失告訴了我們關於腦再生科技控股的什麼信息?
機構投資者往往會避開那些規模太小、流動性太差或風險太高的公司,這些公司對他們的口味來説太小了。但在沒有任何機構投資者的情況下,看到較大的公司並不常見。
一家公司可能沒有在股票登記處登記任何機構的原因有很多。如果流動性(每天交易的股票數量)很低,機構可能很難購買大量股票。如果該公司不需要籌集資金,機構可能缺乏建立頭寸的機會。或者,該公司可能有某些方面讓機構投資者望而卻步。機構投資者可能不會覺得這項業務的歷史性增長令人印象深刻,或者可能有其他因素在起作用。你可以在下面看到腦再生科技控股過去的收入表現,為你自己。
納斯達克CM:RGC收益和收入增長2022年11月16日
腦再生科技控股並非為對衝基金所有。該公司首席執行官歐逸傑是最大股東,持有81%的流通股。擁有如此龐大的股份,我們推斷他們對公司的未來有很大的控制權。當內部人持有公司大量股份時,這通常被認為是一個好兆頭,在這種情況下,我們很高興看到公司內部人士有這樣的皮膚。與此同時,第二大和第三大股東分別持有7.6%和0.05%的流通股。
研究機構持股是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒,也可以達到同樣的效果。據我們所知,沒有分析師對該公司的報道,所以它很可能在雷達下飛行。
腦再生科技控股的內部人所有權
儘管對內部人的準確定義可能是主觀的,但幾乎每個人都認為董事會成員是內部人。公司管理層管理企業,但首席執行官將向董事會負責,即使他或她是董事會成員。
我通常認為內部人持股是一件好事。然而,在某些情況下,這會讓其他股東更難讓董事會對決策負責。
看來,內部人士持有腦再生科技控股有限公司一半以上的股份。這給了他們很大的權力。因此,他們在這項價值3.97億美元的業務中持有3.22億美元的股份。大多數人會辯稱,這是積極的,表明了與股東的強烈一致。你可以點擊這裏,看看這些內部人士是一直在買入還是賣出。
一般公有制
包括散户投資者在內的普通公眾持有該公司11%的股份,因此不能輕易忽視。儘管這種規模的所有權可能不足以影響有利於他們的政策決定,但他們仍然可以對公司政策產生集體影響。
私募股權所有權
私募股權公司持有腦再生科技控股7.6%的股份。這表明,他們可以在關鍵的政策決策中發揮影響力。一些人可能會喜歡這樣,因為私人股本有時是讓管理層承擔責任的積極分子。但在其他時候,私募股權公司讓公司上市後,它們的股票都賣光了。
接下來的步驟:
我發現看看到底是誰擁有一家公司是非常有趣的。但為了真正獲得洞察力,我們還需要考慮其他信息。比如風險。每家公司都有它們,我們已經發現腦再生科技控股的2個警告信號(其中1個有點不愉快!)你應該知道。
當然了這可能不是最值得購買的股票。。因此,您可能希望看到我們的免費一組有趣的潛在客户,擁有有利的財務狀況。
注:本文中的數字是使用過去12個月的數據計算的,指的是截至財務報表日期的最後一個月的12個月期間。這可能與全年的年度報告數字不一致。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。